New atlas details immune cell changes as disease progresses
Researchers in Belgium have developed an atlas to mark changes in distinct types of immune cells during multiple myeloma’s  progression. Their work, in…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreResearchers in Belgium have developed an atlas to mark changes in distinct types of immune cells during multiple myeloma’s  progression. Their work, in…
The U.S. Food and Drug Administration (FDA) will review GSK’s request to approve Blenrep (belantamab mafodotin) as part of a combination treatment for adults…
A combination therapy using Blenrep (belantamab mafodotin) was more effective at extending life in people with relapsed or refractory multiple myeloma than a combo treatment…
A standard autologous hematopoietic stem cell transplant (AHSCT) safely and effectively prolongs survival and delays cancer progression in adults with multiple myeloma, a…
The subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) has been approved in the European Union as part of a combination treatment for adults with newly…
Johnson & Johnson (J&J) is asking regulatory authorities in the European Union to approve a combination treatment based on the subcutaneous, or under-the-skin, formulation…